A pilot trial to evaluate the acute toxicity and feasibility of (Jordan et al., 1980; Jordan 1981) . In humans epidemiological evidence supports the hypothesis that this mechanism may be important in the promotion of breast cancer (Miller & Bulbrook, 1980) . This raises the therapeutic possibility that endocrine intervention could prevent breast cancer, (Cusick et al., 1986) but it seems unlikely that more extensive epidemiological studies will adequately test this hypothesis.
An alternative approach would be to undertake a clinical trial using an effective anti-oestrogenic intervention in high risk women. This would not only provide evidence as to whether anti-oestrogenic intervention could prevent breast cancer, but also give strong indications about mechanisms of carcinogenesis in human breast cancer.
The epidemiological studies of breast cancer incidence following the atomic bomb explosions in Japan in 1945 indicate that ovarian function is required for endocrine promotion of radiation induced breast cancers. The incidence of breast cancer did not start to increase until about 13 years after radiation (Tokunaga et al., 1979) and continues to increase 30 years later (Tokunaga et al., 1984) . This would suggest that endocrine prevention trials would require long periods of follow-up before any beneficial effects could be detected.
The number of women required for a prevention trial will depend on the number of cancers which eventually develop in the trial population. This, in turn, is a function of the relative risk of women chosen, the duration of follow-up and the magnitude of the preventative effect. In order to detect a 75% reduction only 15 breast cancers need to develop in the test population, whereas 300 cancers would be required in order to detect a 25% reduction. For unselected women in the UK aged between 35 and 65, the risk of breast cancer is approximately 1.75 per 1,000 per year (Cancer Statistics, 1984) whereas women aged 50-60 with a first degree female family history of breast cancer have a risk of 5-6 per 1,000 per year. Of these high risk women, 5,000 will develop 250-300 cancers over a 10-year follow-up period.
Thus, in order to have a reasonable chance of detecting significant prevention by anti-oestrogenic intervention, approximately 5,000 high-risk women would be required, with a 10-20 year follow-up. Were compliance maintained at only 50%, four times this number of women would be needed. This requires that the anti-oestrogenic intervention be well tolerated and easy to administer and maintain.
There are various anti-oestrogenic options available. A low fat diet may reduce oestrogenic activity (Rose et al., 1987) but strict dietary control is required and it is unlikely that this could be maintained for the time required for adequate protection. Non-randomised studies indicate that oophorectomy or ovarian irradiation will substantially reduce the incidence of breast cancer, the degree of protection being related to age at ablation (MacMahon & Feinlieb, 1960; Hirayama & Wynder, 1962 (Key & Pike, 1988) .
Tamoxifen, a relatively seective anti-oestrogen, is effective treatment for endocrine sensitive breast cancer with virtually no side-effects (Cole et al., Ward, 1973) . When given to women with primary breast cancer it delays relapse and prolongs survival (Scottish Breast Cancer Trials Report, 1987; Nato Report, 1980; CRC Report, 1988) . It is also an effective treatment for primary breast cancer in some elderly patients (Bradbeer & Kyngdon, 1983) . Tamoxifen has been used to treat breast cancer since 1969 and no untoward longterm side effects have been identified in humans. Furthermore, preliminary toxicity studies indicate that tamoxifen is not anti-oestrogenic on other important tissues in the body, such as bone (Fentiman et al., 1988) , where lack of oestrogen could promote osteoporosis. Mutagenicity studies have indicated that, like oestrogen, tamoxifen at high dosages can cause bepatocellular cancer in the rat (DeWaard & Wang, 1988) . Tamoxifen is generally oestrogenic in the rat and this effect is similar to that seen with the oral contraceptive pill. Hepatocellular cancer has not been reported in women taking tamoxifen and it appears likely that this risk is very small (Fentiman & Powles, 1987) . With regard to other tumours,.experimental evidence indicates that tamoxifen may be oestrogenic on the endometrium (Gottardis & Robinson, 1988 ) with a potential associated risk of causing endometrial cancer (Hardell, 1988; Jordan, 1988 (Fornander et al., 1989) , although this has not been confirmed in the Scottish trial giving adjuvant tamoxifen 20 mg day-for 5 years (Steward & Knight, 1989 At the commencement of the trial, the women were clinically assessed for breast abnormalities, with mammography, breast ultrasound and needle aspiration cytology where indicated. Post-randomisation, the women were seen at 3 and 6 months and then every 6 months for clinical examination, assessment of compliance and acute toxicity. During the development of this feasibility trial further monitoring was incorporated into the protocol as detailed below.
When possible serum oestradiol (E2) and sex hormone binding globulin (SHBG) were measured pre-treatment and at 3, 6, 9, 12, 18 and 24 months, in peri, post-menopausal and post-hysterectomy women. Pre-menopausal women had luteal and follicular-phase bloods taken pre-treatment and repeated at the above intervals. Serum was stored for other hormone measurements at a later stage.
The clotting factors anti-thrombin 3 and fibrinogen were measured if possible every 6 months along with a fasting lipid profile of total cholesterol, HDL cholesterol and tnrglyceride.
Some women in this study reported lower abdominal pains possibly caused by the development of ovarian cysts. We therefore undertook sequential pelvic ultrasound on a subsection of women using an Acuson scanner.
The risk of causing or aggravating osteoporosis by antioestrogenic intervention indicated a need for sequential measurement of bone mass. Hormone dependent bone mass can be adequately monitored by single photon absorption through the forearm using a bone densitometer (ND 110 Nuclear Data Inc.) (Christiansan & Rodbro, 1977; Christiansan et al., 1981) . This was repeated at 6-monthly intervals for the first 2 years and will be continued annually.
It is planned to continue medication, monitoring and screening in these 200 women for as long as is acceptable in order to gain information regarding long-term compliance and toxicity.
Results
Until the stricter consent cnteria were instituted in February 1988, 76 eligible women with at least one first degree relative with breast cancer consented to enter the trial from the EDU compared to 50 women for the SBC. From February 1988 to October 1988, 61 women from the EDU consented compared to 13 from the SBC (Table I) .
After the change in eligibility criteria and consent in February 1988, a subpopulation of 242 women attending the EDU with a family history of breast cancer were assessed for reasons of non-eligibility and non-consent (Table II) . Although an average of 11.5 women with a family history of breast cancer attended the clinic only an average of 2.7 were eligible, 47% of whom consented to inclusion after informed consent. Details of the reasons for ineligibility and nonconsent are given in Table II .
For all 200 women randomised the age, menopausal status and extent of family history were similar for the tamoxifen and placebo women (Table III) . Compliance to medication for the first year, as assessed by interview, was high and the same for both groups. This reflects the relatively low toxicity for tamoxifen versus placebo (Table IV) . Apart from hot flushes which occurred in 27% of tamoxifen women versus 11% of placebo women (P<0.005) there was no significant differences between the two types of medication.
Non-compliance related to toxicity was similar for both groups of women, with seven tamoxifen and six placebo women temporarily stopping medication. Permanent cessation of medication occurred in 18 tamoxifen versus 12 placebo women (n.s.) (Table V) . Ovarian ultrasound was carried out in 19 women before the start of medication and 38 women up to one year later (Table VI) . Five (25%) of the 20 women on tamoxifen had at least one ovarian cyst identified compared to two of 19 pre-treatment and none of 18 post-placebo women (i.e. a total of two cysts (4%) in 37 non-tamoxifen women). Sequential pelvic ultrasound studies continue on as many women as possible in order to assess the clinical significance of these findings.
Clotting studies were undertaken in as many women as possible at various times during the trial, measuring levels of fibrinogen and anti-thrombin 3 (Figure 1 ). There was a nonsignificant trend towards lower levels of fibrinogen, and, to a lesser extent, anti-thrombin 3 for women on tamoxifen. 'Including two non-starters. There was also a trend for a lower fibrinogen/anti-thrombin 3 ratio, which would possibly favour protection against pathological thrombosis. Most women in the trial are now included in these studies.
For logistic reasons it was initially difficult to organise a system for measurement of fasting lipids. However, this is now underway and women have fasting blood samples taken whenever possible before commencement of medication.
Although the information to date shows no differences in tnglycerides, HDL cholesterol or uric acid, levels of total cholesterol are significantly lower for women on tamoxifen (Figure 2 ). Our normal total cholesterol ranges from 3.6 to 6.8 mmol I-1. For sequential measurements in 49 women the mean change in plasma cholesterol levels on placebo was -0.08 mmol 1-1 (95% confidence limits +0.27 to -0.42) compared to -0.85 mmol 1-1 (95% confidence limits -0.45 to -1.25) (P= 0.02) for those on tamoxifen.
Measurement of bone mineral content showed no evidence of increased bone mineral loss for women on tamoxifen (Figure 3 ). Furthermore, tamoxifen had no effect on bone mineral loss in pre-menopausal compared to postmenopausal women.
We have undertaken preliminary measurements of serum E2 and SHBG in some women. There was no difference in pre-treatment and post-treatment SHBG levels in 20 women who received placebo (mean -2.6 nmol 1-1, 95% CI, +5 nmol 1-I to -10 nmol I -1) compared to a significant increase for women on tamoxifen (mean + 14 nmol I 1, 95% CI, +21 nmol I1 to +8 nmol 11, P<0.001). There was no difference in pre-and on-treatment levels of serum oestradiol for 14 post-menopausal women on placebo (mean -8 pmol 1-1 95% CI +7 pmol 1 -1 to -23 pmol I-1) or tamoxifen (mean +5 pmol 1-1 95% CI, +50 pmol I1-to -40 pmol I-1). In contrast there was a significant increase in on-treatment levels of serum oestradiol for 16 pr-eopua wome who reeie eihe taoie (me [. _._,, an (Jordan, 1986) and SHBG in pre-and postmenopausal women (Sakai et al., 1978) . Further analyses of sequential changes in other hormones are underway. (Sakai et al., 1978; Rossner & Wallgren, 1984) . The effects that these changes may have on the incidence of coronary heart disease or atherosclerosis are difficult to predict. It would seem that a rise in HDL cholesterol and a lowering in LDL cholesterol and thereby total cholesterol is beneficial (Bush & Miller, 1987; Bush & Barratt-Connor, 1985) . We are therefore undertaking more extensive lipid studies to answer these questions.
Changes in clotting factors with a lowering of the fibrinogen/anti-thrombin 3 ratio may indicate a decreased risk of thrombosis, especially if this is further enhanced by a significant reduction in serum cholesterol. This may account for an apparent decrease in non-cancer deaths in two major adjuvant trials (Scottish Trial Report, 1987; Nato Report, 1980) . Sequential pelvic ultrasound examination in a small subgroup of women failed to detect a significant effect of tamoxifen on the ovaries or uterus. At this stage it would appear that any possible increased risk of ovarian or uterine cancer is outweighed by a potential reduced risk of cardiovascular disease. It is possible that a long-term, unexpected and serious toxicity of tamoxifen may be identified in the future, but at this stage it would seem that this is small compared with the probability of developing breast cancer in these high risk women. It is anticipated that regular breast, ovarian, uterine, lipid and clotting screening, together with a possible reduction in cardiovascular deaths, would more than outweigh any potential unknown risks.
The results from this feasibility trial indicate that it would be possible to accrue sufficient high risk women into a national programme. This would be assisted by identification of high risk eligible women within the national screening programme. Accrual of 5,000 women with at least two first degrees female relatives could probably be achieved within 5 years. Using tamoxifen or placebo, adequate compliance could be maintained in order to detect a 25% prevention effect at 10-15 years.
Problems of work load and cost are likely to be significant. The cost of tamoxifen and placebo for the feasibility trial is approximately thirty pounds per woman, per year of medication. The cost of active screening of 5,000 women, together with the added extra supervision required for medication and toxicity assessment, would need to be considered within a national programme of screening and prevention.
In conclusion, these preliminary results indicate that tamoxifen, a proven anti-proliferative agent for endocrine sensitive breast cancer, is, for the most part, not antioestrogenic in other tissues of the body. This selective activity, with possible long-term benefits for bone and vascular disease, together with its low acute toxicity, makes it an ideal agent for a trial of endocrine prevention of breast cancer.
Further progress on the developments of a national multicentre trial will now depend on extended ethical approval and the.-upport of such bodies as the Breast Cancer Trials Co-ordinating Sub-committee and the Cancer Research Campaign, or other national cancer research bodies.
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